Medtronic (NYSE:MDT) FY Earnings Call Presentation

Business Strategy & Portfolio - Medtronic is focused on innovation to accelerate revenue and earnings growth, executing on generational growth drivers like PFA portfolio, Symplicity™, Altaviva™, and Hugo™ RAS[6] - The company intends to separate its Diabetes business, which currently accounts for $12.5 billion in revenue[9] - Medtronic is focused on the highest margin growth drivers where it has leading core competencies[8] Key Growth Opportunities - The Pulsed Field Ablation (PFA) market is estimated to be >$13 billion and growing at +25% annually[22] - Renal Denervation with Symplicity Spyral™ represents a multi-billion dollar opportunity, with 1% penetration of U.S patients equating to >$1 billion in revenue[27] - Altaviva™ Tibial Neuromodulation for Urge Urinary Incontinence presents a $1 billion revenue opportunity based on ~1% penetration of the 5M U.S patients actively seeking advanced therapies[33] - The company aims to double revenue in one of the fast-growing MedTech segments[16] Innovation & Technology - Medtronic is positioned to lead in Pulsed Field Ablation with a comprehensive product portfolio, expecting Sphere-360™ U.S Pivotal Approval by 1HFY27[22] - Symplicity Spyral™ is a breakthrough treatment for high blood pressure, targeting 18M patients in the U.S with uncontrolled hypertension[26] - Hugo™ system reimagines robotic-assisted surgery, beginning purposeful launch with urologic indication[39] Financial Performance & Strategy - Medtronic is driving innovation across its entire portfolio to achieve durable revenue acceleration in attractive MedTech markets[43] - The company is accelerating value creation through growth, disciplined operations, increased investment in R&D, and strategic M&A[46] - Medtronic expects to generate $2 billion CAS Revenue from $1 billion revenue in FY25[24]